Latest news

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies

Debiopharm Collaborates With Innocentive For The Launch of A Global Challenge To Develop A Single-Dose mRNA Covid-19 Vaccine

Debiopharm Launches the “IDEAL” Initiative to Strengthen the Lemanic Region as a Hub for Life Science Innvovation

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant

Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients

Le Challenge 2020 pour la qualité de vie du patient récompense le projet Oculus de sonnette connectée actionnée par le…

Phase II Research Against Covid-19 Launched in France with Debiopharm’s Antiviral Alisporivir

Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform